Standout Papers
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease (2014)
- Axonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer's Disease (2005)
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease (2013)
- Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease (2010)
- The Preclinical Alzheimer Cognitive Composite (2014)
- Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia (2020)
- Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals (2020)
- Trial of Solanezumab in Preclinical Alzheimer’s Disease (2023)
- The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease (2022)
Immediate Impact
8 from Science/Nature 81 standout
Citing Papers
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
2025 Standout
The epidemiology of Parkinson's disease
2024 Standout
Works of Rema Raman being referenced
Early-stage Alzheimer disease: getting trial-ready
2022
Plasma Urate and Progression of Mild Cognitive Impairment
2008
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Rema Raman | 3161 | 4406 | 2146 | 2206 | 225 | 12.5k | |
| Matti Viitanen | 5538 | 4844 | 1545 | 2199 | 282 | 16.0k | |
| Mary Sano | 4813 | 3343 | 1346 | 1453 | 251 | 12.5k | |
| Gunhild Waldemar | 5026 | 2618 | 1498 | 2493 | 346 | 12.9k | |
| Kathleen A. Welsh‐Bohmer | 5726 | 4863 | 1048 | 1486 | 231 | 14.3k | |
| Kamal Masaki | 3875 | 5465 | 1524 | 2694 | 264 | 17.8k | |
| Rhoda Au | 6039 | 4579 | 2550 | 1813 | 297 | 17.7k | |
| Raimo Sulkava | 3932 | 3704 | 972 | 1465 | 222 | 12.5k | |
| Krista L. Lanctôt | 5388 | 3841 | 2076 | 1217 | 440 | 19.5k | |
| Melville R. Klauber | 2299 | 4144 | 3177 | 4970 | 152 | 20.8k | |
| Keith Wesnes | 3782 | 2607 | 1034 | 1980 | 315 | 16.3k |
All Works
Login with ORCID to disown or claim papers
Loading papers...